Eva Morava-Kozicz
This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG
Inclusion Criteria * Molecular confirmation of SLC35A2 genetic variant * Age \> 1 month * Presence of seizures, chronic vomiting, chronic constipation, or chronic diarrhea * A parent or legal guardian must be available and willing to provide consent on behalf of minor subjects or adult subjects who are unable to give informed consent due to developmental disabilities. * Use of contraception in females \> age 8 years * Previously performed eye exam within last year Exclusion Criteria * Aldolase-B deficiency * Galactosemia * Hemolytic uremic syndrome * Hemoglobin \< 7 mg/dL * LFTs \> 3x ULN *…
Medical grade D-galactose dosage:2.0 g/kg/day
Matching placebo
Arctuva estimate
Verify or correct the compensation shown for this listing.